Showing results (451-460 of 472) with videos related to

Sort By:
Pageof 48
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 8, 2018
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trialsPierre I Karakiewicz, Emanuele Zaffuto, Anil Kapoor, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 15, 2023
Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statementAly-Khan A Lalani, Anil Kapoor, Naveen S Basappa, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|August 6, 2017
Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC)Luke T Lavallée, Ryan Fitzpatrick, Lori A Wood, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 21, 2024
Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forumFred Saad, Sebastien J Hotte, Krista Noonan, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
ACS Pharmacology & Translational Science|March 29, 2020
Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16INK4a-Negative CancerNam Hoon Kwon, Jin Young Lee, Ye-Lim Ryu, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 9, 2019
Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forumFred Saad, Christina Canil, Antonio Finelli, et al.
The Lancet. Oncology|March 1, 2023
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label studyToni K Choueiri, Masatoshi Eto, Robert Motzer, et al.
Cell Reports|April 7, 2021
Fusion peptide priming reduces immune responses to HIV-1 envelope trimer baseAngela R Corrigan, Hongying Duan, Cheng Cheng, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 14, 2021
Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providersFred Saad, Sebastien J Hotte, Antonio Finelli, et al.
Pageof 48